Matt Plavan work email
- Valid
- Valid
Matt Plavan personal email
- Valid
Matt Plavan phone numbers
Accomplished senior executive with 30 years of successful leadership and board member experience in public and privately held companies within the ag-tech, medical device, cell therapy and healthcare industries. Recognized for ability to identify and capitalize on new market opportunities through the development of effective business strategies and follow-through execution of enterprise-wide growth initiatives. Experienced in the identification and diligence of complex deal structuring and negotiations, leading major acquisitions and organizational integrations with a proven ability to raise capital for growth and expansion. Closed >$200M in equity and debt financing to date.◄Executive Leadership◄Public Company Board Governance◄Strategy & Execution◄Market Development & Commercialization◄Debt & Capital Market Equity Funding◄Venture & Private Equity◄Business Transformation◄Corporate Development & Growth◄M&A, Joint Ventures◄P&L Management◄Risk Mitigation◄Building Corporate Partnerships ◄Product Distribution◄Integration Strategy & Execution◄Go-To-Market Strategies◄Financial Management
-
Chief Financial OfficerOrigin Materials Oct 2023 - PresentWest Sacramento, California, Us -
Board MemberIngredientwerks Oct 2023 - Present -
Chief Executive OfficerIngredientwerks May 2022 - Oct 2023At IngredientWerks, we enhance the natural protein capacity in plants to sustainably design and produce customized ingredients for the best taste, quality and cost for the rapidly growing alternative protein market.
-
Chief Executive Officer & Board MemberArcadia Biosciences Sep 2019 - Dec 2021Davis, California, UsArcadia Biosciences (Nasdaq:RKDA) is a producer and marketer of innovative, plant-based health and wellness products within the portfolios of GoodWheat™ and Lief™, which includes popular brands Soul Spring™, ProVault™, Saavy Naturals® and Zola® coconut water. Developed strategy and oversaw the successful transition from an agricultural biotechnology trailblazer to a dynamic revenue generating consumer food products company targeting on-trend wellness and wheat-based ingredient categories with disruptive nutrition density. To date, raised $75M in equity capital, closed three acquisitions and divested the HB4 soybean assets in sale to Bioceres in 2020 for $30M in cash and $10M in royalty revenues totalling a 3.1x ROI. Also, achieved record revenues in 2020, up over 6x. -
Chief Financial OfficerArcadia Biosciences Sep 2016 - Aug 2019Davis, California, UsRecruited by Board to partner with new CEO to perform corporate strategy review, recommend and lead optimal go-to-market strategy and commercialization plan, including new business model validation, IR/PR launch campaign, company financing strategy execution and amplification of corporate governance.
-
Chief Executive Officer & Board MemberCesca Therapeutics Inc. (Nasdaq:Kool) 2012 - 2015Led transformation of medical device manufacturer, ThermoGenesis, Corp. into fully integrated, world-class regenerative medicine company, Cesca Therapeutics. Grew market cap over 450% to a high of $80M following release in January 2014 of breakthrough clinical trial results. Significantly enhanced liquidity (12-fold increase in shares traded (144 million) in 2014 vs. 2013. Completed two capital equity financings (PIPE and Registered Direct) totaling $18M to fund pivotal clinical trial and organizational integration. Achieved majority shareholder approval of strategic and transformative acquisition of TotipotentRX Corporation valued at $27M. Integrated the two geographic and culturally distinct organizations after merger, leveraging newly implemented employee key core values driven culture.
-
Evp Global Business Development & Chief Financial OfficerCesca Therapeutics Inc. (Nasdaq:Kool) 2010 - 2012In charge of all transactions essential to grow base of business globally and build key business strategic alliances. Initiated critical divestitures of non-core assets maximizing stockholder return and company focus. Added over a dozen new distributors, restructuring global distribution, maximizing productivity and realigned global network by consolidating sales and customer support, thereby regaining market share control in domestic and European cord blood business. Secured regulatory approvals for advanced cord blood processing product in China, India, Thailand, Korea, Singapore, and Japan which resulted in the opening of Asia Automated Cord Blood market, first mover status and enabling global market expansion.
-
Chief Operating Officer & Chief Financial OfficerCesca Therapeutics Inc. (Nasdaq:Kool) 2009 - 2010Led engineering, R&D, and manufacturing, including supply chain, product assembly and contract manufacturing. Reestablished product specifications and clear lines of production responsibility by design component, reforming ineffective single-source disposable contract manufacturer, improving manufacturing yields by 25%. Then doubled disposable production capacity to over 120K units per year and lowered per unit costs by 20%, by securing offshore, second source FDA approved, ISO 13485 Certified Class II and III contract manufacturer.
-
Interim Chief Executive Officer & Chief Financial OfficerCesca Therapeutics Inc. (Nasdaq:Kool) 2008 - 2009Appointed by Board of Director to serve as interim organization leader and provide direction during search for CEO.
-
Chief Financial OfficerCesca Therapeutics Inc. (Nasdaq:Kool) 2005 - 2008Established and handled all relationships with institutional and retail investors, media outlets, Wall Street analysts and private equity firms. Led capital financing and non-deal road shows, and quarterly investor calls, including preparation of earnings releases and conference call scripts. Directed SOX/SEC reporting, strategic planning, budgeting and management reporting. Negotiated and secured $40M in equity capital via secondary offering and PIPE financings, underwritten by Deutsche Bank Securities, Jefferies and Co. & Houlihan Lokey.
-
Chief Financial OfficerStrionair 2002 - 2005Carrier Corp., unit of United Technologies Corp. (NYSE: UTX), acquired StrionAir in 2009. Company developed and patented electronic filtration methods and products, including only whole-house air purifier on market validated by third-party testing to both capture and kill airborne germs, viruses, and mold. Instrumental in supporting launch of company by raising venture and private equity capital. Closed $5M initial bridge financing and Series A Venture with Sequel Venture Partners, Vista Ventures, and Solstice Capital. Closed $11M Series B Venture Capital funding led by The Carlyle Group with Series A investors participating pro-rata, achieving >10% increase in valuation over previous round.
-
Chief Financial OfficerReason, Inc. 2000 - 2002Wireless management services company. Drove parallel path due diligence efforts, supporting six month Series B financing road show and corporate M&A activity, achieving profitable acquisition of company by InPhonic (formerly NASDAQ: INPC) in 2002. -
Vice President Of Finance, ImckessonMckesson 1999 - 2000Irving, Texas, UsSelected by Chairman as founding executive member to combine and structure operations for newly formed $300M, 1,300 employee e-Health subsidiary, iMcKesson. Led accounting and finance organization. -
General Manager, Disease State ManagementMckesson Jul 1998 - Jun 1999Irving, Texas, UsFollowing McKesson's acquisition of Access Health, Inc., repositioned and restructured underperforming strategic business unit comprised of 10 direct and 45 indirect reports, including 40 telephonic-based registered nurses.
-
Senior Director, Investor Relations, Access Health Inc.Mckesson 1995 - 1998Irving, Texas, UsPrior to McKesson's acquisition of Access Health, developed and managed investor relations program, as Access Health grew annual revenues from $32M to $160M and earnings ten-fold.
-
Controller, Managed CareAccess Health Inc. 1993 - 1995Managed accounting operations for $30M business unit.
-
Audit ManagerErnst & Young 1987 - 1993London, GbDirected and performed financial audits and SEC filings for publicly held audit client, including Calgene, SureWest, and Access Health Marketing.
Matt Plavan Skills
Matt Plavan Education Details
-
Uc Santa BarbaraBusiness Economics
Frequently Asked Questions about Matt Plavan
What company does Matt Plavan work for?
Matt Plavan works for Origin Materials
What is Matt Plavan's role at the current company?
Matt Plavan's current role is Executive Officer & Board Member.
What is Matt Plavan's email address?
Matt Plavan's email address is ma****@****hoo.com
What is Matt Plavan's direct phone number?
Matt Plavan's direct phone number is +191653*****
What schools did Matt Plavan attend?
Matt Plavan attended Uc Santa Barbara.
What skills is Matt Plavan known for?
Matt Plavan has skills like Strategic Planning, Cross Functional Team Leadership, Finance, Mergers And Acquisitions, Strategy, Start Ups, Executive Management, Medical Devices, Business Strategy, Process Improvement, Product Development, Business Development.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial